User login
Roundup on Cosmetic Dermatology
A supplement to Skin & Allergy News.
This supplement was produced in affiliation with Skin Disease Education Foundation's Cosmetic Dermatology Seminar and Skin & Allergy News.
•Topic Highlights
•Guest Editors
To view the supplement, click the image above.
Topic Highlights
• New Technology Adds Tools to Cosmetic Dermatology
• Extensive Experience Produces Array of Cosmetic Dermatology Devices
• A Refresher on Antioxidants
• How to Spot Neurosis in Cosmetic Candidates
• Peptides
• Cosmetic Practice: Follow Tips to Get Started
Guest Editors
David J. Goldberg, MD, JD
Clinical Professor of Dermatology
Director, Laser Research and Mohs Surgery
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham Law School
New York, N.Y.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Hackensack, N.J.
Consultant: Photo Therapeutics Limited and BioForm Medical, Inc. He discusses the off-label use of poly-L-lactic acid for the treatment of lipoatrophy in non-HIV-patients and the off-label use of calcium hydroxylapatite as a cosmetic filler agent.
Christopher B. Zachary, FRCP
Clinical Professor
Department of Dermatology
Co-Director, Dermatologic Surgery and Laser Center
University of California at San Francisco
Nothing to disclose.
Copyright © 2005 Elsevier Inc.
A supplement to Skin & Allergy News.
This supplement was produced in affiliation with Skin Disease Education Foundation's Cosmetic Dermatology Seminar and Skin & Allergy News.
•Topic Highlights
•Guest Editors
To view the supplement, click the image above.
Topic Highlights
• New Technology Adds Tools to Cosmetic Dermatology
• Extensive Experience Produces Array of Cosmetic Dermatology Devices
• A Refresher on Antioxidants
• How to Spot Neurosis in Cosmetic Candidates
• Peptides
• Cosmetic Practice: Follow Tips to Get Started
Guest Editors
David J. Goldberg, MD, JD
Clinical Professor of Dermatology
Director, Laser Research and Mohs Surgery
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham Law School
New York, N.Y.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Hackensack, N.J.
Consultant: Photo Therapeutics Limited and BioForm Medical, Inc. He discusses the off-label use of poly-L-lactic acid for the treatment of lipoatrophy in non-HIV-patients and the off-label use of calcium hydroxylapatite as a cosmetic filler agent.
Christopher B. Zachary, FRCP
Clinical Professor
Department of Dermatology
Co-Director, Dermatologic Surgery and Laser Center
University of California at San Francisco
Nothing to disclose.
Copyright © 2005 Elsevier Inc.
A supplement to Skin & Allergy News.
This supplement was produced in affiliation with Skin Disease Education Foundation's Cosmetic Dermatology Seminar and Skin & Allergy News.
•Topic Highlights
•Guest Editors
To view the supplement, click the image above.
Topic Highlights
• New Technology Adds Tools to Cosmetic Dermatology
• Extensive Experience Produces Array of Cosmetic Dermatology Devices
• A Refresher on Antioxidants
• How to Spot Neurosis in Cosmetic Candidates
• Peptides
• Cosmetic Practice: Follow Tips to Get Started
Guest Editors
David J. Goldberg, MD, JD
Clinical Professor of Dermatology
Director, Laser Research and Mohs Surgery
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham Law School
New York, N.Y.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Hackensack, N.J.
Consultant: Photo Therapeutics Limited and BioForm Medical, Inc. He discusses the off-label use of poly-L-lactic acid for the treatment of lipoatrophy in non-HIV-patients and the off-label use of calcium hydroxylapatite as a cosmetic filler agent.
Christopher B. Zachary, FRCP
Clinical Professor
Department of Dermatology
Co-Director, Dermatologic Surgery and Laser Center
University of California at San Francisco
Nothing to disclose.
Copyright © 2005 Elsevier Inc.
Acne Vulgaris and Rosacea: Optimizing Therapy
A supplement to Skin & Allergy News.
Supported by an educational grant from Stiefel.
The articles in this supplement are based on presentations made during the Skin Disease Education Foundation's 29th Annual Hawaii Dermatology Seminar, on March 18-24, 2005, in Maui, Hawaii.
•Topics
•Faculty/Faculty Disclosure Statement
•Target Audience
To view the supplement, click the image above.
Topics
• The Importance of Vehicle in Acne Therapy
• Acne Management: Treatment Strategies and Challenges
• Cosmetic Management of Patients with Acne Vulgaris and Acne Rosacea
• The Resurgence of Benzoyl Peroxide in Acne Therapy
• New Treatment Options for Acne Rosacea
Faculty/Faculty Disclosure Statement
Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
Department of Dermatology
University of California, Davis
Medical Director
Center for Dermatology and Laser Surgery
Sacramento, Calif.
Consultant: Stiefel Laboratories, Inc.
Diane S. Berson, MD
Assistant Professor of Dermatology
Weill Medical College of Cornell University
New York, NY
Advisory Boards: Allergan, Inc., Connectics Corporation, Dermik Laboratories, Galderma International, and Medicis Pharmaceuticals Corporation.
Michael H. Gold, MD
Gold Skin Care Center
Nashville, Tenn.
No financial relationships to disclose.
Mary P. Lupo, MD
Clinical Professor of Dermatology
Tulane University Medical School
New Orleans, LA
Consultant: Stiefel Laboratories, Inc., Allergan and Dermik
Barry A. Solomon, MD, JD
Assistant Clinical Professor of Dermatology
Kings County Hospital Center
SUNY Health Science Center
Brooklyn, NY
Consultant: Stiefel Laboratories, Inc. He also discusses the investigational use of clindamycin 1% and benzoyl peroxide 5% for the treatment of acne rosacea.
Target Audience
This activity has been designed for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris and acne rosacea.
Copyright © 2005 by International Medical News Group
A supplement to Skin & Allergy News.
Supported by an educational grant from Stiefel.
The articles in this supplement are based on presentations made during the Skin Disease Education Foundation's 29th Annual Hawaii Dermatology Seminar, on March 18-24, 2005, in Maui, Hawaii.
•Topics
•Faculty/Faculty Disclosure Statement
•Target Audience
To view the supplement, click the image above.
Topics
• The Importance of Vehicle in Acne Therapy
• Acne Management: Treatment Strategies and Challenges
• Cosmetic Management of Patients with Acne Vulgaris and Acne Rosacea
• The Resurgence of Benzoyl Peroxide in Acne Therapy
• New Treatment Options for Acne Rosacea
Faculty/Faculty Disclosure Statement
Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
Department of Dermatology
University of California, Davis
Medical Director
Center for Dermatology and Laser Surgery
Sacramento, Calif.
Consultant: Stiefel Laboratories, Inc.
Diane S. Berson, MD
Assistant Professor of Dermatology
Weill Medical College of Cornell University
New York, NY
Advisory Boards: Allergan, Inc., Connectics Corporation, Dermik Laboratories, Galderma International, and Medicis Pharmaceuticals Corporation.
Michael H. Gold, MD
Gold Skin Care Center
Nashville, Tenn.
No financial relationships to disclose.
Mary P. Lupo, MD
Clinical Professor of Dermatology
Tulane University Medical School
New Orleans, LA
Consultant: Stiefel Laboratories, Inc., Allergan and Dermik
Barry A. Solomon, MD, JD
Assistant Clinical Professor of Dermatology
Kings County Hospital Center
SUNY Health Science Center
Brooklyn, NY
Consultant: Stiefel Laboratories, Inc. He also discusses the investigational use of clindamycin 1% and benzoyl peroxide 5% for the treatment of acne rosacea.
Target Audience
This activity has been designed for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris and acne rosacea.
Copyright © 2005 by International Medical News Group
A supplement to Skin & Allergy News.
Supported by an educational grant from Stiefel.
The articles in this supplement are based on presentations made during the Skin Disease Education Foundation's 29th Annual Hawaii Dermatology Seminar, on March 18-24, 2005, in Maui, Hawaii.
•Topics
•Faculty/Faculty Disclosure Statement
•Target Audience
To view the supplement, click the image above.
Topics
• The Importance of Vehicle in Acne Therapy
• Acne Management: Treatment Strategies and Challenges
• Cosmetic Management of Patients with Acne Vulgaris and Acne Rosacea
• The Resurgence of Benzoyl Peroxide in Acne Therapy
• New Treatment Options for Acne Rosacea
Faculty/Faculty Disclosure Statement
Emil A. Tanghetti, MD, Chair
Clinical Professor of Dermatology
Department of Dermatology
University of California, Davis
Medical Director
Center for Dermatology and Laser Surgery
Sacramento, Calif.
Consultant: Stiefel Laboratories, Inc.
Diane S. Berson, MD
Assistant Professor of Dermatology
Weill Medical College of Cornell University
New York, NY
Advisory Boards: Allergan, Inc., Connectics Corporation, Dermik Laboratories, Galderma International, and Medicis Pharmaceuticals Corporation.
Michael H. Gold, MD
Gold Skin Care Center
Nashville, Tenn.
No financial relationships to disclose.
Mary P. Lupo, MD
Clinical Professor of Dermatology
Tulane University Medical School
New Orleans, LA
Consultant: Stiefel Laboratories, Inc., Allergan and Dermik
Barry A. Solomon, MD, JD
Assistant Clinical Professor of Dermatology
Kings County Hospital Center
SUNY Health Science Center
Brooklyn, NY
Consultant: Stiefel Laboratories, Inc. He also discusses the investigational use of clindamycin 1% and benzoyl peroxide 5% for the treatment of acne rosacea.
Target Audience
This activity has been designed for healthcare professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with acne vulgaris and acne rosacea.
Copyright © 2005 by International Medical News Group
Selected Issues in Dermatology
A supplement to Skin & Allergy News.
Supported by an educational grant from Stiefel.
The articles in this supplement are based on a faculty interview and reviews of selected posters that were presented at a medical conference held February 18-22, 2005, in New Orleans.
•Contents
•Faculty/Faculty Disclosure Statement
To view the supplement, click the image above.
Contents
• Combination Tazarotene and Clindamycin/Benzoyl Peroxide
• Use of Clindamycin 1%/Benzoyl Peroxide 5% Gel Alone and in Combination for Acne Vulgaris
• Patient Preference for Clindamycin/Benzoyl Peroxide Gel Formulations
• Quantitative Assessment of the Application and Consumption of Topical Acne Medication by Patients
• Sulfacetamide/Sulfur Combination With Sunscreen for Rosacea
Faculty/Faculty Disclosure Statement
James Q. Del Rosso, DO, FAOCD
University of Nevada
School of Medicine
Las Vegas
Received funding for clinical grants: Galderma S.A., Intendis Inc., Medicis Pharmaceutical Corporations, Stiefel Laboratories, Inc.
Consultant: Galderma, Intendis, Stiefel.
He discusses the use of metronidazole and azelaic acid as a once-a-day treatment for rosacea as opposed to twice daily.
Copyright © 2005 by International Medical News Group
A supplement to Skin & Allergy News.
Supported by an educational grant from Stiefel.
The articles in this supplement are based on a faculty interview and reviews of selected posters that were presented at a medical conference held February 18-22, 2005, in New Orleans.
•Contents
•Faculty/Faculty Disclosure Statement
To view the supplement, click the image above.
Contents
• Combination Tazarotene and Clindamycin/Benzoyl Peroxide
• Use of Clindamycin 1%/Benzoyl Peroxide 5% Gel Alone and in Combination for Acne Vulgaris
• Patient Preference for Clindamycin/Benzoyl Peroxide Gel Formulations
• Quantitative Assessment of the Application and Consumption of Topical Acne Medication by Patients
• Sulfacetamide/Sulfur Combination With Sunscreen for Rosacea
Faculty/Faculty Disclosure Statement
James Q. Del Rosso, DO, FAOCD
University of Nevada
School of Medicine
Las Vegas
Received funding for clinical grants: Galderma S.A., Intendis Inc., Medicis Pharmaceutical Corporations, Stiefel Laboratories, Inc.
Consultant: Galderma, Intendis, Stiefel.
He discusses the use of metronidazole and azelaic acid as a once-a-day treatment for rosacea as opposed to twice daily.
Copyright © 2005 by International Medical News Group
A supplement to Skin & Allergy News.
Supported by an educational grant from Stiefel.
The articles in this supplement are based on a faculty interview and reviews of selected posters that were presented at a medical conference held February 18-22, 2005, in New Orleans.
•Contents
•Faculty/Faculty Disclosure Statement
To view the supplement, click the image above.
Contents
• Combination Tazarotene and Clindamycin/Benzoyl Peroxide
• Use of Clindamycin 1%/Benzoyl Peroxide 5% Gel Alone and in Combination for Acne Vulgaris
• Patient Preference for Clindamycin/Benzoyl Peroxide Gel Formulations
• Quantitative Assessment of the Application and Consumption of Topical Acne Medication by Patients
• Sulfacetamide/Sulfur Combination With Sunscreen for Rosacea
Faculty/Faculty Disclosure Statement
James Q. Del Rosso, DO, FAOCD
University of Nevada
School of Medicine
Las Vegas
Received funding for clinical grants: Galderma S.A., Intendis Inc., Medicis Pharmaceutical Corporations, Stiefel Laboratories, Inc.
Consultant: Galderma, Intendis, Stiefel.
He discusses the use of metronidazole and azelaic acid as a once-a-day treatment for rosacea as opposed to twice daily.
Copyright © 2005 by International Medical News Group
Nonmelanoma Skin Cancers: Research and Clinical Findings with Immune Response Modifier Therapy
A supplement to Skin & Allergy News.
This educational supplement was supported by a restricted educational grant from 3M Pharmaceuticals.
The presentations took place at a symposium held on November 19, 2004 in Florence, Italy.
To view the supplement, click the image above.
Topics Highlights/Faculty
Introduction
Professor Alberto Giannetti, MD, Chair
Professor of Dermatology
Department of Dermatology and Director of the Specializing School in Dermatology and Venereology
University of Modena
Italy
Nothing to disclose.
Professor Wolfram Sterry, MD, Co-Chair
Professor, Department of Dermatology Chair
Charité University Hospital
Humboldt University
Berlin, Germany
Received funding for clinical grants from 3M, Coley Pharmaceutical Group, Inc., and Shire Pharmaceuticals Group plc.
The Histopathology of Nonmelanoma Skin Caners: Overview of Recent Findings
Professor Helmut Kerl, MD
Professor and Chairman
Department of Dermatology
Medical University of Graz
Austria
Consultant to 3M.
The Emerging Potential of Immune Response Modifier Therapy in Superficial Skin Cancers
Professor Reinhard Dummer, MD
Professor of the Department of Dermatology
University Hospital of Zurich
Switzerland
Consultant to 3M Pharmaceuticals. He discusses the investigational use of imiquimod in treating mycosis fungoides, cutaneous T-cell lymphomas, and lentigo maligna.
The Role of Imiquimod in the Treatment of BCC: Clinical Evidence
Professor Nicole Basset-Séguin, MD, PhD
Professor in Dermatology
Hôpital Saint-Louis
Paris, France
Nothing to disclose.
Illuminating the Mode of Action of Immune Response Modifier Therapy in Superficial Skin Cancers
Professor Dr med Eggert Stockfleth
Head of Derm-Oncology Department
Clinic for Dermatology, Venereology and Allergy
University School of Medicine, Charité
Berlin, Germany
Discusses the investigational use of immune response modifiers as oral therapy in patients with hepatitis infections and as an adjuvant for vaccines.
Copyright © 2005 by International Medical News Group
A supplement to Skin & Allergy News.
This educational supplement was supported by a restricted educational grant from 3M Pharmaceuticals.
The presentations took place at a symposium held on November 19, 2004 in Florence, Italy.
To view the supplement, click the image above.
Topics Highlights/Faculty
Introduction
Professor Alberto Giannetti, MD, Chair
Professor of Dermatology
Department of Dermatology and Director of the Specializing School in Dermatology and Venereology
University of Modena
Italy
Nothing to disclose.
Professor Wolfram Sterry, MD, Co-Chair
Professor, Department of Dermatology Chair
Charité University Hospital
Humboldt University
Berlin, Germany
Received funding for clinical grants from 3M, Coley Pharmaceutical Group, Inc., and Shire Pharmaceuticals Group plc.
The Histopathology of Nonmelanoma Skin Caners: Overview of Recent Findings
Professor Helmut Kerl, MD
Professor and Chairman
Department of Dermatology
Medical University of Graz
Austria
Consultant to 3M.
The Emerging Potential of Immune Response Modifier Therapy in Superficial Skin Cancers
Professor Reinhard Dummer, MD
Professor of the Department of Dermatology
University Hospital of Zurich
Switzerland
Consultant to 3M Pharmaceuticals. He discusses the investigational use of imiquimod in treating mycosis fungoides, cutaneous T-cell lymphomas, and lentigo maligna.
The Role of Imiquimod in the Treatment of BCC: Clinical Evidence
Professor Nicole Basset-Séguin, MD, PhD
Professor in Dermatology
Hôpital Saint-Louis
Paris, France
Nothing to disclose.
Illuminating the Mode of Action of Immune Response Modifier Therapy in Superficial Skin Cancers
Professor Dr med Eggert Stockfleth
Head of Derm-Oncology Department
Clinic for Dermatology, Venereology and Allergy
University School of Medicine, Charité
Berlin, Germany
Discusses the investigational use of immune response modifiers as oral therapy in patients with hepatitis infections and as an adjuvant for vaccines.
Copyright © 2005 by International Medical News Group
A supplement to Skin & Allergy News.
This educational supplement was supported by a restricted educational grant from 3M Pharmaceuticals.
The presentations took place at a symposium held on November 19, 2004 in Florence, Italy.
To view the supplement, click the image above.
Topics Highlights/Faculty
Introduction
Professor Alberto Giannetti, MD, Chair
Professor of Dermatology
Department of Dermatology and Director of the Specializing School in Dermatology and Venereology
University of Modena
Italy
Nothing to disclose.
Professor Wolfram Sterry, MD, Co-Chair
Professor, Department of Dermatology Chair
Charité University Hospital
Humboldt University
Berlin, Germany
Received funding for clinical grants from 3M, Coley Pharmaceutical Group, Inc., and Shire Pharmaceuticals Group plc.
The Histopathology of Nonmelanoma Skin Caners: Overview of Recent Findings
Professor Helmut Kerl, MD
Professor and Chairman
Department of Dermatology
Medical University of Graz
Austria
Consultant to 3M.
The Emerging Potential of Immune Response Modifier Therapy in Superficial Skin Cancers
Professor Reinhard Dummer, MD
Professor of the Department of Dermatology
University Hospital of Zurich
Switzerland
Consultant to 3M Pharmaceuticals. He discusses the investigational use of imiquimod in treating mycosis fungoides, cutaneous T-cell lymphomas, and lentigo maligna.
The Role of Imiquimod in the Treatment of BCC: Clinical Evidence
Professor Nicole Basset-Séguin, MD, PhD
Professor in Dermatology
Hôpital Saint-Louis
Paris, France
Nothing to disclose.
Illuminating the Mode of Action of Immune Response Modifier Therapy in Superficial Skin Cancers
Professor Dr med Eggert Stockfleth
Head of Derm-Oncology Department
Clinic for Dermatology, Venereology and Allergy
University School of Medicine, Charité
Berlin, Germany
Discusses the investigational use of immune response modifiers as oral therapy in patients with hepatitis infections and as an adjuvant for vaccines.
Copyright © 2005 by International Medical News Group
New Directions in the Treatment of Melasma
A supplement to Skin & Allergy News supported by an unrestricted educational grant from Galderma.
Highlights of clinical dialogues with the faculty.
To view the supplement, click the image above.
Contents
Melasma and the Challenges of Treating Skin of Color
Leslie S. Baumann, MD
Director, Division of Cosmetic Dermatology
Department of Dermatology
University of Miami
Clinical Grants: Hill Dermaceuticals and Galderma Laboratories, L.P. Advisory Board: Medicis Pharmaceutical Corporation. Consultant: Stiefel.
Clinical Pharmacology and Safety of a Novel Triple-Combination Agent in the Treatment of Melasma
Helen Mary Torok, MD
Clinical Advisor
Marietta College, Physicians Assistant Program
Marietta, Ohio
HMT Dermatology Associates, Inc.
Medina, Ohio
Consultant: Galderma
Efficacy of a Novel Triple-Combination Agent in the Treatment of Facial Melasma
Susan C. Taylor, MD
Assistant Clinical Professor of Dermatology
College of Physicians and Surgeons
Columbia University
Director, Skin of Color Center
St. Luke's Roosevelt Hospital Center
New York
Clinical Grants: Hill Dermaceuticals and Galderma. Consultant: Galderma
Copyright © 2002 by International Medical News Group
A supplement to Skin & Allergy News supported by an unrestricted educational grant from Galderma.
Highlights of clinical dialogues with the faculty.
To view the supplement, click the image above.
Contents
Melasma and the Challenges of Treating Skin of Color
Leslie S. Baumann, MD
Director, Division of Cosmetic Dermatology
Department of Dermatology
University of Miami
Clinical Grants: Hill Dermaceuticals and Galderma Laboratories, L.P. Advisory Board: Medicis Pharmaceutical Corporation. Consultant: Stiefel.
Clinical Pharmacology and Safety of a Novel Triple-Combination Agent in the Treatment of Melasma
Helen Mary Torok, MD
Clinical Advisor
Marietta College, Physicians Assistant Program
Marietta, Ohio
HMT Dermatology Associates, Inc.
Medina, Ohio
Consultant: Galderma
Efficacy of a Novel Triple-Combination Agent in the Treatment of Facial Melasma
Susan C. Taylor, MD
Assistant Clinical Professor of Dermatology
College of Physicians and Surgeons
Columbia University
Director, Skin of Color Center
St. Luke's Roosevelt Hospital Center
New York
Clinical Grants: Hill Dermaceuticals and Galderma. Consultant: Galderma
Copyright © 2002 by International Medical News Group
A supplement to Skin & Allergy News supported by an unrestricted educational grant from Galderma.
Highlights of clinical dialogues with the faculty.
To view the supplement, click the image above.
Contents
Melasma and the Challenges of Treating Skin of Color
Leslie S. Baumann, MD
Director, Division of Cosmetic Dermatology
Department of Dermatology
University of Miami
Clinical Grants: Hill Dermaceuticals and Galderma Laboratories, L.P. Advisory Board: Medicis Pharmaceutical Corporation. Consultant: Stiefel.
Clinical Pharmacology and Safety of a Novel Triple-Combination Agent in the Treatment of Melasma
Helen Mary Torok, MD
Clinical Advisor
Marietta College, Physicians Assistant Program
Marietta, Ohio
HMT Dermatology Associates, Inc.
Medina, Ohio
Consultant: Galderma
Efficacy of a Novel Triple-Combination Agent in the Treatment of Facial Melasma
Susan C. Taylor, MD
Assistant Clinical Professor of Dermatology
College of Physicians and Surgeons
Columbia University
Director, Skin of Color Center
St. Luke's Roosevelt Hospital Center
New York
Clinical Grants: Hill Dermaceuticals and Galderma. Consultant: Galderma
Copyright © 2002 by International Medical News Group
Case 1: Management Decisions in an Adult Comorbid Patient With Type 2 Diabetes Having Primary HyperlipidemiaCase 2: Colesevelam Hydrochloride for Management of a Patient With Type 2 Diabetes Mellitus and Hyperlipidemia
Case 2: Colesevelam Hydrochloride for Management of a Patient With Type 2 Diabetes Mellitus and Hyperlipidemia
A Case Studies Compendium supplement to Internal Medicine News. This supplement was sponsored by Daiichi Sankyo, Inc.
•Case 1 Topics
•Case 2 Topics
•Faculty/Faculty Disclosures
To view the supplement, click the image above.
Case 1 Topics
• Background
• Current Visit
• Laboratory Results
• Clinical Discussion
• Endocrinologist Consultation
• New Treatment Regimen With Add-On Therapy
• Conclusions
Case 2 Topics
• Background
• Current Visit: Exam Findings
• Current Treatment Regimen
• Health History
• Laboratory Results
• Clinical Discussion
• Cardiologist Visit
• Three Months After Visiting the Cardiologist
• Add-On Therapy With Welchol for Patients With T2DM and CHD
• Treatment Goals for Alice
• Conclusions
Faculty/Faculty Disclosures
Yehuda Handelsman, MD, FACP, FACE
Medical Director
Metabolic Institute of America
Chair and Program Director
7th World Congress on InsulinResistance
Chair, International Committeefor Insulin Resistance
18372 Clark Street, Suite 212
Tarzana, CA 91356
E-mail:[email protected]
Web Site:www.TheMetabolicCenter.com
Dr Handelsman is a consultant for Bristol-Myers Squibb
Company, Daiichi Sankyo, Inc., GlaxoSmithKline, Medtronic, Merck, Tethys,
and Xoma; he has received clinical research grant funding from Daiichi Sankyo, Inc., GlaxoSmithKline, Novo Nordisk, and Takeda; and he ison the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Inc., GlaxoSmithKline, Merck, and Novartis. He also serves on the advisory board for CLINICAL ENDOCRINOLOGY NEWS.
Peter H. Jones, MD, FACP
Co-Director, Lipid Metabolism
and Atherosclerosis Clinic
Medical Director, Weight
Management Center
The Methodist Hospital
Associate Professor of Medicine
Section of Atherosclerosis andLipid Research
Baylor College of Medicine
Houston, TX 77030
E-mail: [email protected]
Dr Jones has disclosed that he has received support in the form of consulting agreements from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo, Inc., and Merck.
Copyright © 2010 Elsevier Inc.
A Case Studies Compendium supplement to Internal Medicine News. This supplement was sponsored by Daiichi Sankyo, Inc.
•Case 1 Topics
•Case 2 Topics
•Faculty/Faculty Disclosures
To view the supplement, click the image above.
Case 1 Topics
• Background
• Current Visit
• Laboratory Results
• Clinical Discussion
• Endocrinologist Consultation
• New Treatment Regimen With Add-On Therapy
• Conclusions
Case 2 Topics
• Background
• Current Visit: Exam Findings
• Current Treatment Regimen
• Health History
• Laboratory Results
• Clinical Discussion
• Cardiologist Visit
• Three Months After Visiting the Cardiologist
• Add-On Therapy With Welchol for Patients With T2DM and CHD
• Treatment Goals for Alice
• Conclusions
Faculty/Faculty Disclosures
Yehuda Handelsman, MD, FACP, FACE
Medical Director
Metabolic Institute of America
Chair and Program Director
7th World Congress on InsulinResistance
Chair, International Committeefor Insulin Resistance
18372 Clark Street, Suite 212
Tarzana, CA 91356
E-mail:[email protected]
Web Site:www.TheMetabolicCenter.com
Dr Handelsman is a consultant for Bristol-Myers Squibb
Company, Daiichi Sankyo, Inc., GlaxoSmithKline, Medtronic, Merck, Tethys,
and Xoma; he has received clinical research grant funding from Daiichi Sankyo, Inc., GlaxoSmithKline, Novo Nordisk, and Takeda; and he ison the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Inc., GlaxoSmithKline, Merck, and Novartis. He also serves on the advisory board for CLINICAL ENDOCRINOLOGY NEWS.
Peter H. Jones, MD, FACP
Co-Director, Lipid Metabolism
and Atherosclerosis Clinic
Medical Director, Weight
Management Center
The Methodist Hospital
Associate Professor of Medicine
Section of Atherosclerosis andLipid Research
Baylor College of Medicine
Houston, TX 77030
E-mail: [email protected]
Dr Jones has disclosed that he has received support in the form of consulting agreements from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo, Inc., and Merck.
Copyright © 2010 Elsevier Inc.
A Case Studies Compendium supplement to Internal Medicine News. This supplement was sponsored by Daiichi Sankyo, Inc.
•Case 1 Topics
•Case 2 Topics
•Faculty/Faculty Disclosures
To view the supplement, click the image above.
Case 1 Topics
• Background
• Current Visit
• Laboratory Results
• Clinical Discussion
• Endocrinologist Consultation
• New Treatment Regimen With Add-On Therapy
• Conclusions
Case 2 Topics
• Background
• Current Visit: Exam Findings
• Current Treatment Regimen
• Health History
• Laboratory Results
• Clinical Discussion
• Cardiologist Visit
• Three Months After Visiting the Cardiologist
• Add-On Therapy With Welchol for Patients With T2DM and CHD
• Treatment Goals for Alice
• Conclusions
Faculty/Faculty Disclosures
Yehuda Handelsman, MD, FACP, FACE
Medical Director
Metabolic Institute of America
Chair and Program Director
7th World Congress on InsulinResistance
Chair, International Committeefor Insulin Resistance
18372 Clark Street, Suite 212
Tarzana, CA 91356
E-mail:[email protected]
Web Site:www.TheMetabolicCenter.com
Dr Handelsman is a consultant for Bristol-Myers Squibb
Company, Daiichi Sankyo, Inc., GlaxoSmithKline, Medtronic, Merck, Tethys,
and Xoma; he has received clinical research grant funding from Daiichi Sankyo, Inc., GlaxoSmithKline, Novo Nordisk, and Takeda; and he ison the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Inc., GlaxoSmithKline, Merck, and Novartis. He also serves on the advisory board for CLINICAL ENDOCRINOLOGY NEWS.
Peter H. Jones, MD, FACP
Co-Director, Lipid Metabolism
and Atherosclerosis Clinic
Medical Director, Weight
Management Center
The Methodist Hospital
Associate Professor of Medicine
Section of Atherosclerosis andLipid Research
Baylor College of Medicine
Houston, TX 77030
E-mail: [email protected]
Dr Jones has disclosed that he has received support in the form of consulting agreements from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo, Inc., and Merck.
Copyright © 2010 Elsevier Inc.
Case 2: Colesevelam Hydrochloride for Management of a Patient With Type 2 Diabetes Mellitus and Hyperlipidemia
Case 2: Colesevelam Hydrochloride for Management of a Patient With Type 2 Diabetes Mellitus and Hyperlipidemia
An Approach to the Management of Type 2 Diabetes Mellitus in Patients Receiving Add-On Therapy With Colesevelam HCl
A Journal Scan supplement to Family Practice News
A Journal Scan supplement to Family Practice News
A Journal Scan supplement to Family Practice News
CASE STUDY: Management Decisions in a Comorbid Patient With Type 2 Diabetes Having Primary Hyperlipidemia
A supplement to Internal Medicine News. This supplement was sponsored by Daiichi Sankyo, Inc.
•Topics
•Faculty/Faculty Disclosures
To view the supplement, click the image above.
Topics
• Background
• Current Visit
• Laboratory Results
• Clinical Discussion
• Endocrinologist Consultation
• New Treatment Regimen With Add-On Therapy
• Conclusions
Faculty
Yehuda Handelsman, MD, FACP, FACE
Medical Director, Metabolic Institute of America
Chair and Program Director, 7th World Congress on Insulin Resistance Chair, International Committee for Insulin Resistance
18372 Clark Street, Suite 212
Tarzana, CA 91356
E-mail:[email protected]
Web site:www.TheMetabolicCenter.com
Dr Handelsman is a consultant for Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., GlaxoSmithKline, Medtronic, Merck, Xoma, and Tethys;he has received clinical research grant funding from Takeda, Daiichi Sankyo Inc., GlaxoSmithKline, and Novo Nordisk; and he is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo Inc., GlaxoSmithKline, Merck, and Novartis. He also serves on the advisory board for CLINICAL ENDOCRINOLOGY NEWS.
Copyright © 2010 Elsevier Inc.
A supplement to Internal Medicine News. This supplement was sponsored by Daiichi Sankyo, Inc.
•Topics
•Faculty/Faculty Disclosures
To view the supplement, click the image above.
Topics
• Background
• Current Visit
• Laboratory Results
• Clinical Discussion
• Endocrinologist Consultation
• New Treatment Regimen With Add-On Therapy
• Conclusions
Faculty
Yehuda Handelsman, MD, FACP, FACE
Medical Director, Metabolic Institute of America
Chair and Program Director, 7th World Congress on Insulin Resistance Chair, International Committee for Insulin Resistance
18372 Clark Street, Suite 212
Tarzana, CA 91356
E-mail:[email protected]
Web site:www.TheMetabolicCenter.com
Dr Handelsman is a consultant for Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., GlaxoSmithKline, Medtronic, Merck, Xoma, and Tethys;he has received clinical research grant funding from Takeda, Daiichi Sankyo Inc., GlaxoSmithKline, and Novo Nordisk; and he is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo Inc., GlaxoSmithKline, Merck, and Novartis. He also serves on the advisory board for CLINICAL ENDOCRINOLOGY NEWS.
Copyright © 2010 Elsevier Inc.
A supplement to Internal Medicine News. This supplement was sponsored by Daiichi Sankyo, Inc.
•Topics
•Faculty/Faculty Disclosures
To view the supplement, click the image above.
Topics
• Background
• Current Visit
• Laboratory Results
• Clinical Discussion
• Endocrinologist Consultation
• New Treatment Regimen With Add-On Therapy
• Conclusions
Faculty
Yehuda Handelsman, MD, FACP, FACE
Medical Director, Metabolic Institute of America
Chair and Program Director, 7th World Congress on Insulin Resistance Chair, International Committee for Insulin Resistance
18372 Clark Street, Suite 212
Tarzana, CA 91356
E-mail:[email protected]
Web site:www.TheMetabolicCenter.com
Dr Handelsman is a consultant for Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., GlaxoSmithKline, Medtronic, Merck, Xoma, and Tethys;he has received clinical research grant funding from Takeda, Daiichi Sankyo Inc., GlaxoSmithKline, and Novo Nordisk; and he is on the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo Inc., GlaxoSmithKline, Merck, and Novartis. He also serves on the advisory board for CLINICAL ENDOCRINOLOGY NEWS.
Copyright © 2010 Elsevier Inc.
JOURNAL SCANSummary of Key ArticlesIdentifying Challenges With Insulin Therapy and Assessing Treatment Strategies With Pramlintide
Summary of Key Articles
Identifying Challenges With Insulin Therapy and Assessing Treatment Strategies With Pramlintide
A supplement to Internal Medicine News.
This supplement was sponsored by Amylin.
•Topics
•Faculty/Faculty Disclosures
To view the supplement, click the image above.
Topics
• Introduction
• Should Minimal Blood Glucose Variability Become the Gold Standard of Glycemic Control?
• Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients
• Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
• Effects of Intensive Glucose Lowering in Type 2 Diabetes
• Pramlintide as an Adjunct to Insulin in Patients With Type 2 Diabetes in a Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, and Weight
• Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-Year Randomized Controlled Trial
• Amylin Replacement with Primlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Type 1 Diabetes Mellitus: A 1-Year, Randomized Controlled Trial
• Important Safety Information and SYMLIN Prescribing Information
Faculty/Faculty Disclosure
Steven V. Edelman, MD
Professor of Medicine, University of California, San Diego
Veterans Affairs Medical Center, San Diego, California
Founder and Director, Taking Control of Your Diabetes, 501(3)
Del Mar, California
Associate Clinical Professor of Medicine
Dr. Edelman is a consultant to and speaker for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, and sanofi-aventis U.S., LLC.
A supplement to Internal Medicine News.
This supplement was sponsored by Amylin.
•Topics
•Faculty/Faculty Disclosures
To view the supplement, click the image above.
Topics
• Introduction
• Should Minimal Blood Glucose Variability Become the Gold Standard of Glycemic Control?
• Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients
• Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
• Effects of Intensive Glucose Lowering in Type 2 Diabetes
• Pramlintide as an Adjunct to Insulin in Patients With Type 2 Diabetes in a Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, and Weight
• Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-Year Randomized Controlled Trial
• Amylin Replacement with Primlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Type 1 Diabetes Mellitus: A 1-Year, Randomized Controlled Trial
• Important Safety Information and SYMLIN Prescribing Information
Faculty/Faculty Disclosure
Steven V. Edelman, MD
Professor of Medicine, University of California, San Diego
Veterans Affairs Medical Center, San Diego, California
Founder and Director, Taking Control of Your Diabetes, 501(3)
Del Mar, California
Associate Clinical Professor of Medicine
Dr. Edelman is a consultant to and speaker for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, and sanofi-aventis U.S., LLC.
A supplement to Internal Medicine News.
This supplement was sponsored by Amylin.
•Topics
•Faculty/Faculty Disclosures
To view the supplement, click the image above.
Topics
• Introduction
• Should Minimal Blood Glucose Variability Become the Gold Standard of Glycemic Control?
• Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic Patients
• Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
• Effects of Intensive Glucose Lowering in Type 2 Diabetes
• Pramlintide as an Adjunct to Insulin in Patients With Type 2 Diabetes in a Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, and Weight
• Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes: A 1-Year Randomized Controlled Trial
• Amylin Replacement with Primlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Type 1 Diabetes Mellitus: A 1-Year, Randomized Controlled Trial
• Important Safety Information and SYMLIN Prescribing Information
Faculty/Faculty Disclosure
Steven V. Edelman, MD
Professor of Medicine, University of California, San Diego
Veterans Affairs Medical Center, San Diego, California
Founder and Director, Taking Control of Your Diabetes, 501(3)
Del Mar, California
Associate Clinical Professor of Medicine
Dr. Edelman is a consultant to and speaker for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, and sanofi-aventis U.S., LLC.
Summary of Key Articles
Identifying Challenges With Insulin Therapy and Assessing Treatment Strategies With Pramlintide
Summary of Key Articles
Identifying Challenges With Insulin Therapy and Assessing Treatment Strategies With Pramlintide
Practical Neuroscience for Primary Care Physicians: Summer 2008
A supplement to Family Practice News and Internal Medicine News.
TOPIC HIGHLIGHTS/FACULTY
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Clinical Implications of Depression in Patients With Cardiovascular Disease
Alexander Glassman, MD
Professor of Clinical Psychiatry
College of Physicians and Surgeons
Columbia University
Chief, Clinical Psychopharmacology
New York State Psychiatric Institute
New York, N.Y.
Dr. Glassman has nothing to disclose.
Practical Bits: Quick and Practical Diagnostic Tools
Case Files
• Depression or Anxiety?
• ADHD or Anxiety?
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr. Schwartz has disclosed that he is a consultant to Wyeth. He has also received funding for clinical grants from Wyeth, Forest Laboratories, Inc., and Bristol-Myers Squibb Company.
Strategies for Managing Patients with Migraine
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Cambridge, Mass.
Medical Director, Women's Headache Center
Somerville, Mass.
Dr. Bernstein has nothing to disclose.
A supplement to Family Practice News and Internal Medicine News.
TOPIC HIGHLIGHTS/FACULTY
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Clinical Implications of Depression in Patients With Cardiovascular Disease
Alexander Glassman, MD
Professor of Clinical Psychiatry
College of Physicians and Surgeons
Columbia University
Chief, Clinical Psychopharmacology
New York State Psychiatric Institute
New York, N.Y.
Dr. Glassman has nothing to disclose.
Practical Bits: Quick and Practical Diagnostic Tools
Case Files
• Depression or Anxiety?
• ADHD or Anxiety?
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr. Schwartz has disclosed that he is a consultant to Wyeth. He has also received funding for clinical grants from Wyeth, Forest Laboratories, Inc., and Bristol-Myers Squibb Company.
Strategies for Managing Patients with Migraine
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Cambridge, Mass.
Medical Director, Women's Headache Center
Somerville, Mass.
Dr. Bernstein has nothing to disclose.
A supplement to Family Practice News and Internal Medicine News.
TOPIC HIGHLIGHTS/FACULTY
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Clinical Implications of Depression in Patients With Cardiovascular Disease
Alexander Glassman, MD
Professor of Clinical Psychiatry
College of Physicians and Surgeons
Columbia University
Chief, Clinical Psychopharmacology
New York State Psychiatric Institute
New York, N.Y.
Dr. Glassman has nothing to disclose.
Practical Bits: Quick and Practical Diagnostic Tools
Case Files
• Depression or Anxiety?
• ADHD or Anxiety?
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr. Schwartz has disclosed that he is a consultant to Wyeth. He has also received funding for clinical grants from Wyeth, Forest Laboratories, Inc., and Bristol-Myers Squibb Company.
Strategies for Managing Patients with Migraine
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Cambridge, Mass.
Medical Director, Women's Headache Center
Somerville, Mass.
Dr. Bernstein has nothing to disclose.
